iBio, Inc.
IBIO · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 77.8% | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 100% | 100% | – | -101.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -4,259.8% | -6,231.6% | – | -1,365.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -4,594.3% | -11,069.8% | – | -2,674.7% |
| EPS Diluted | -1.75 | -6.5 | -23.94 | -58.49 |
| % Growth | 73.1% | 72.8% | 59.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |